Salisbury Foundation Trust


Internal Reference Number: FOI_5934

Date Request Received: 27/11/2020 15:16:44

Date Request Replied To: 14/12/2020 11:23:05

This response was sent via: By Email

Request Summary: treatment of CRC

Request Category: Researcher

Question Number 1:
I am researching the incidence and treatment of Colorectal Cancer (CRC). Could you please tell me how many patients your trust has treated in the past 3 months with the following agents for colorectal cancer [CRC]?

• Aflibercept
• Bevacizumab
• Capecitabine
• Cetuximab in combination with FOLFIRI
• Cetuximab in combination with FOLFOX
• Cetuximab not in combination with FOLFIRI or FOLFOX
• Irinotecan
• Oxaliplatin
• Panitumumab in combination with FOLFIRI
• Panitumumab in combination with FOLFOX
• Panitumumab not in combination with FOLFIRI or FOLFOX
• Nivolumab
• Raltitrexed
• Ramucirumab
• Regorafenib
• Sorafenib
• 5FU only
• Tegafur Uracil + 5FU
• Trifluridine–tipiracil
• Other
Answer To Question 1:
These are the regimens we have used and the numbers, all others will be zero:

Capecitabine single agent: 7
Oxaliplatin: 1 (with raltitrexed below)
Panitumumab with FOLFIRI: 2
Panitumumab with FOLFOX: 1
Raltitexed: 1
Trifluridine-tipiracil: 3
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E:
© 2021 Salisbury NHS Foundation Trust
Trust Values